Navigation Links
Breast MRI Scan Could Determine Need for Radiation Therapy

SEATTLE, Sept. 21 /PRNewswire/ -- For women whose breast cancer has spread to their lymph nodes, a magnetic resonance imaging (MRI) scan could replace exploratory surgery as the method for determining whether those women need radiation therapy to treat their disease, according to a study to be presented during the annual meeting of the American Society for Therapeutic Radiology and Oncology (ASTRO) which opens today in Boston.

In a retrospective study of 167 patients who underwent radiation therapy for invasive breast cancer after surgical staging of their tumors, physician researchers at the Seattle Cancer Care Alliance and University of Washington Medical Center found that the tumors' physiological information shown on MRI scans correlated with surgically based findings of cancer having spread to lymph nodes. This suggests that breast MRI could help determine if women scheduled to undergo surgery will later need radiation therapy and how much.

The findings are significant because the standard of care for women with breast cancer has evolved during the past five years. In the past, decisions regarding radiation therapy were made after surgery and before chemotherapy, according to lead author Christopher Loiselle, M.D., a resident in the Department of Radiation Oncology at UW Medical Center. Today, increasing numbers of women may be treated with chemotherapy before surgery.

"When you give chemotherapy first, and then perform the surgery to remove the cancer and sample the lymph nodes, you reduce your ability to know whether there was cancer in the axillary (underarm) lymph nodes before the patient was treated with chemotherapy," Loiselle said. "This raises the question: is there another way to stage those lymph nodes? Our study showed that tumor characteristics as seen on an MRI scan may be the answer."

The ultimate benefit is that some women can be spared radiation therapy, especially those with smaller tumors and tumors that have not spread to the lymph nodes, he said.

A contrast dye used routinely in MRI scans not only highlights the size and location of the tumor but also details the blood vessels feeding the tumor. The kinetics or activity of the contrast dye in the tumor provided some key parameters for comparing MRI to traditional surgical tumor staging, he said.

"MRI is evolving rapidly as a diagnostic tool for breast cancer, particularly among women with high risk for the disease, because not only does it give us traditional anatomic information about tumors but information about the biology of the tumor as well," Loiselle said.

Prospective studies will need to be done to confirm the value of MRI scans in staging tumors for radiation therapy, he said.

About Seattle Cancer Care Alliance

Seattle Cancer Care Alliance, established in 1998, unites the adult and pediatric cancer-care services of Fred Hutchinson Cancer Research Center, UW Medicine and Children's Hospital and Regional Medical Center. A major focus of SCCA is to speed the transfer of new diagnostic and treatment techniques from the research setting to the patient bedside while providing premier, patient-focused cancer care. Patients who come to SCCA receive the latest research-based cancer therapies as well as cutting-edge treatments for a number of non-malignant diseases under development by its partner organizations. SCCA has three clinical-care sites: an outpatient clinic on the Fred Hutchinson campus, a pediatric-inpatient unit at Children's and an adult-inpatient unit at UW Medical Center. For more information about SCCA, visit

Media Contact:

Dean Forbes, 206-667-2896

SOURCE Seattle Cancer Care Alliance
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Xeloda XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
3. Xeloda(R) XeNA Study Analyses of Xeloda, Docetaxel and Herceptin Combination Therapy for Metastatic Breast Cancer Featured at Major New Breast Cancer Symposium
4. Kosans Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
7. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women
8. New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
9. Symbollon Pharmaceuticals, Inc. Evaluates the Clinical Effects of IoGen(TM) on Fibrocystic Breast Disease
10. Spit for the Cure Offers Unique Opportunity for Women to Participate in Breast Cancer Research
11. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
Post Your Comments:
(Date:9/25/2017)... , Sept. 25, 2017   Montrium , ... File solutions, today—from the IQPC Trial Master Files ... , NL)—announced that EastHORN Clinical Services has selected ... programs and TMF management. EastHORN, a leading European ... platform to increase transparency to enable greater collaboration ...
(Date:9/19/2017)... venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed sound ... ... Jim Bertolina, PhD ... Tom Tefft ... device executive Josh Stopek , PhD, who has led R&D and business development teams ...
(Date:9/12/2017)... and NEW YORK , Sept. 12, 2017   ... for global supply chains, has published the first annual edition of its ... of more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings ... 2016. ... CSR Risk & Performance Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... 13, 2017 , ... The International Association of Eating Disorders ... for the field of eating disorders, announces the opening of early registration for ... Florida at the Omni Resort at ChampionsGate. , The annual iaedp™ ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... ... ... Talented host, actor Rob Lowe, is introducing a segment ... of "Success Files," which is an award-winning educational program broadcasted on PBS Member ... with passion and integrity. , Sciatica occurs when the sciatic nerve in the ...
(Date:10/12/2017)... Francisco, CA (PRWEB) , ... October 12, 2017 ... ... Dr. Cheng, are now treating sleep apnea using cutting-edge Oventus O2Vent ... apnea, a serious sleep disorder characterized by frequent cessation in breathing. Oral appliances ...
(Date:10/12/2017)... ... , ... Asante, a nationally recognized health system in southern ... home health joint venture through an agreement, effective October 1, 2017, to create ... health company with Asante, delivering clinically integrated care, for the past eight years. ...
Breaking Medicine News(10 mins):